Antiproliferative Activities of Cynaropicrin and Related Compounds against Cancer Stem Cells

Kousuke Araki1, Minami Hara1, Shohei Hamada1

  • 1Kyoto Pharmaceutical University.

PubMed

Insights

Cynaropicrin, a sesquiterpenoid, shows potent antiproliferative activity against glioblastoma stem cells. This compound and its derivatives may lead to new drugs targeting these resistant cancer stem cells.

Area of Science:

  • Natural Products Chemistry
  • Cancer Biology
  • Medicinal Chemistry

Background:

  • Glioblastoma (GBM) exhibits high mortality due to treatment resistance.
  • Cancer stem cells (CSCs) drive GBM progression, metastasis, and therapeutic resistance.
  • There is an urgent need for novel CSC-targeting drugs.

Purpose of the Study:

  • To evaluate the antiproliferative potential of 21 sesquiterpenoids against GBM CSCs.
  • To identify lead compounds for developing new anti-GBM therapies.

Main Methods:

  • Screening of 21 sesquiterpenoids for antiproliferative activity against U-251 MG CSCs and non-CSCs.
  • Synthesis and structure-activity relationship (SAR) analysis of six cynaropicrin derivatives.
  • Identification of key structural moieties responsible for activity.

Main Results:

  • Cynaropicrin (1) demonstrated significant antiproliferative effects on both GBM CSCs and non-CSCs.
  • Guaianolide sesquiterpene lactones with the α-methylene-γ-butyrolactone moiety were active.
  • The 5,7,5-ring system and the α-methylene-γ-butyrolactone moiety are crucial for activity.

Conclusions:

  • Cynaropicrin is a promising lead compound for developing novel anti-GBM CSC drugs.
  • The α,β-unsaturated carbonyl moiety in cynaropicrin is identified as the active center.
  • Further research into cynaropicrin derivatives could yield effective CSC-targeting therapies.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K